Valuation: LivaNova PLC

Market Cap 4.53B 3.94B 3.68B 3.37B 6.36B 432B 6.47B 43.34B 16.97B 215B 17.01B 16.64B 710B P/E 2026 *
29.6x
P/E 2027 * 25.6x
Enterprise Value 4.53B 3.94B 3.68B 3.37B 6.36B 432B 6.47B 43.34B 16.97B 215B 17.01B 16.64B 710B EV / Sales 2026 *
3x
EV / Sales 2027 * 2.81x
Free-Float
98.44%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 2024-02-29
Director of Finance/CFO 56 2020-10-30
Investor Relations Contact - 2022-07-31
Director TitleAgeSince
Director/Board Member 69 2015-10-18
Chairman 74 2021-06-08
Director/Board Member 62 2019-06-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.64% - - 4.53B
+1.34%+2.52%-15.85%-0.39% 185B
+1.51%+2.92%-2.98%+2.59% 111B
-0.95%-0.89%+6.94%+61.15% 60B
+2.63%+9.46%+43.51%+59.34% 53.9B
+2.77%+7.10%-3.49%-36.65% 46.9B
+3.03%+1.94% - - 34.22B
+4.63%+19.00%+10.13%-28.48% 32.95B
+2.05%+5.04%+45.42%-5.89% 24.49B
+1.86%+6.52%+2.54%+3.17% 22.67B
Average +1.89%+5.16%+10.78%+6.85% 63.49B
Weighted average by Cap. +1.70%+3.77%+1.55%+8.10%

Financials

2026 *2027 *
Net sales 1.51B 1.31B 1.22B 1.12B 2.12B 144B 2.15B 14.43B 5.65B 71.68B 5.66B 5.54B 236B 1.61B 1.4B 1.31B 1.2B 2.27B 154B 2.31B 15.45B 6.05B 76.74B 6.06B 5.93B 253B
Net income 148M 129M 120M 111M 208M 14.14B 212M 1.42B 556M 7.05B 557M 545M 23.27B 179M 156M 146M 134M 252M 17.1B 256M 1.72B 672M 8.53B 674M 659M 28.13B
Net Debt - -
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA